Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Clinical trial NCT04056572 · UNKNOWN
Trial details
- NCT number
- NCT04056572
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-08-13
- Primary completion
- 2021-10-30
- Enrollment
- 135
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.